Tables and Figures

1. Global Asthma Network

Figure. Global Asthma Network Centres at March 2022

Table. Aspirations of the Global Asthma Network

2. Asthma and Factors Affecting it

Figure: Estimated fraction (%) of current wheeze attributable to allergic sensitisation (measured as skin prick test reactivity >3 mm, or presence of allergen-specific IgE in serum)

3. Global Burden of Disease due to Asthma

Figure 1: Prevalence of current asthma symptoms in children aged 6-7

Figure 2: Prevalence of current asthma symptoms in adolescents aged 13-14

Figure 3: Prevalence of current asthma symptoms in adults

Figure 4: GAN Phase I: Severity of asthma symptoms by age group and country income level

4. Hospital Admissions for Asthma

Figure 1. Age-standardised asthma mortality rates (all ages) 2001-2005 and 2011-2015 by country, ranked by 2011-2015 age-standardised mortality rate within World Bank 2014 income group.

Figure 2. Scatter plot of age-standardised asthma mortality rates and age-standardised hospital admission rates for asthma, in European countries providing recent data for both (2001-2015).

Figure 3. Annual change in hospital admission rates for childhood asthma (ages 5-14) by change in prevalence of nocturnal wheezing among 13-14 year olds in countries with one or more ISAAC centres providing prevalence data for both ISAAC Phase One (around 1995) and ISAAC Phase Three (around 2002).

Figure 4. Absolute changes over time in population prevalence of asthma symptoms in surveys of school children conducted by GAN Phase I and ISAAC Phases I and III.

5. Global Asthma Management and Control

Figure 1. Asthma control among children, adolescents, and adults worldwide.

Figure 2. Use of asthma medications according to asthma severity in the past year, in children, adolescents, and adults.

6. COVID-19 and Asthma

Figure 1. Medication changes (%) in asthmatic children infected with SARS-CoV-2.

Figure 2. Symptom severity (%) in asthmatic children infected with SARS-CoV-2.

Table. Change of asthma medicines, severity, treatment and outcomes of COVID-19 in asthmatic children infected with SARS-CoV-2.

7. Asthma in the African Region

South Africa:

Table: Prevalence of current symptoms of asthma (12-month prevalence rate of wheeze) by centre in South Africa 13 - 14 year age group as measured by the International Study of Asthma and Allergies in Childhood (ISAAC) Phases One, Three and the Global Asthma Network (GAN) Phase I.

Spirometry in Africa:

Table. ATS spirometry training course summary across Africa region in the past 5 years."/>

9. Asthma in the Eastern Mediterranean Region

Sudan

Figure 1. Standard Case Management asthma pilot project symptoms before and after follow up.

Figure 2. Number of presumed CRD patients vs number of referrals to a health care facility by area Gezira State - Sudan December 2020 - June 2021.

Figure 3. Categorisation of referred cases Gezira State - Sudan Dec 2020 - June 2021.

Summary:

Table: Prevalences of asthma symptoms in adolescents in the Eastern Mediterranean Region: ISAAC Phase III (1996-2002); GAN Phase I (2016-2020).

12. Asthma in the Western Pacific Region

Taiwan:

Figure 1. Change in asthma prevalence in Taiwan 1995 - 2001 .

New Zealand:

Table: Repeated cross-sectional studies of asthma prevalence in children and adolescents in Auckland.

14. Asthma in the Context of Other Chronic Respiratory Diseases in LMICs

Figure 1. Distribution of the global burden of disease, deaths, and disability adjusted life years (DALYs) from (A) chronic respiratory diseases, (B) chronic obstructive pulmonary disease, and (C) asthma, by World Bank-defined country income per capita strata, using Global Burden of Disease 2019 estimates.

Figure 2. WHO six building blocks of health systems, together with aims and desirable attributes.

15. Improving Access to Essential Asthma Medicines

Figure 1. Availability of asthma and COPD medicines in public pharmacies across the 6 geopolitical zones of Nigeria.

Figure 2. Availability of WHO essential medicines in African countries.

Figure 3. Patient payment method of essential medicines for chronic respiratory diseases.

Table 1a: Actions within countries.

Table 1b: Actions for WHO and its influencers.

Next: Glossary >